Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lacidophilin + vonoprazan + amoxicillin
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Nanchang University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This combination therapy is a multi-component regimen being evaluated for the first-line treatment of *Helicobacter pylori* infection. It consists of lacidophilin (a probiotic containing *Lactobacillus acidophilus*), vonoprazan (a potassium-competitive acid blocker), and amoxicillin (a beta-lactam antibiotic). Vonoprazan suppresses gastric acid production by inhibiting the gastric H+/K+-ATPase pump more potently and for longer durations than traditional proton pump inhibitors, creating an optimal environment for amoxicillin's bactericidal activity. Amoxicillin acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins. Lacidophilin is added to potentially enhance eradication rates and mitigate antibiotic-associated gastrointestinal side effects by modulating the gut microbiota. The regimen is currently being studied in Phase 4 clinical trials led by The First Affiliated Hospital of Nanchang University in China.
- Brand names
- Lacidophilin
- Other names
- Lacidophilin tablets in combination with vonoprazan and amoxicillin dual therapyo-The First Affiliated Hospital of Nanchang University-Helicobacter pylori infection
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)PBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on lacidophilin + vonoprazan + amoxicillin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lacidophilin + vonoprazan + amoxicillin.